WVE highlights positive target engagement for WVE-007 at Research Day

Rhea-AI Filing Summary

Wave Life Sciences (WVE) filed an 8-K announcing a Research Day webcast held on October 29, 2025, and made the slide presentation available on its investor website. The company also furnished a press release summarizing highlights from the event, including positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity.

The materials are provided under Regulation FD as Item 7.01 information furnished, not filed, and thus are not subject to Section 18 liabilities. The press release (other than its second paragraph) is incorporated by reference into Item 8.01. Exhibit 99.1 contains the press release; the cover page interactive data file is included as Exhibit 104.

false 0001631574 0001631574 2025-10-29 2025-10-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2025

WAVE LIFE SCIENCES LTD.

(Exact name of registrant as specified in its charter)

Singapore		001-37627		98-1356880
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

7 Straits View #12-00, Marina One
East Tower
Singapore		018936
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: +65 6236 3388

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol		Name of each exchange on which registered
$0 Par Value Ordinary Shares		WVE		The Nasdaq Global Market

Item 7.01 Regulation FD Disclosure.

On October 29, 2025, Wave Life Sciences Ltd. (the “Company”) hosted a virtual analyst and investor Research Day webcast and shared a slide presentation that is available on the “Investors” section of the Company’s website at http://ir.wavelifesciences.com/.

In addition, on October 29, 2025, the Company issued a press release summarizing the key information presented during the Research Day webcast, including positive target engagement data from the Company’s ongoing INLIGHT clinical trial evaluating WVE-007 for obesity. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Wave Life Sciences Ltd. dated October 29, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WAVE LIFE SCIENCES LTD.
By:		/s/ Paul B. Bolno, M.D.
		Paul B. Bolno, M.D.
		President and Chief Executive Officer

Date: October 29, 2025

FAQ

What did Wave Life Sciences (WVE) announce in its 8-K?

The company hosted a virtual Research Day webcast, posted the slide presentation on its investor website, and furnished a press release as Exhibit 99.1.

What clinical update was highlighted by WVE?

The press release summarized positive target engagement data from the ongoing INLIGHT clinical trial evaluating WVE-007 for obesity.

Is the information considered filed or furnished?

The Research Day information is furnished under Item 7.01 and is not deemed filed or subject to Section 18 liabilities.

What parts are incorporated into Item 8.01?

The information in the press release, other than its second paragraph, is incorporated by reference into Item 8.01.

Where can investors access the materials?

The slide presentation is available on the company’s investor website, and the press release is included as Exhibit 99.1.

Which exhibits were included with the 8-K?

Exhibit 99.1 is the press release dated October 29, 2025, and Exhibit 104 is the cover page interactive data file.